The level of serum carcinoembryonic antigen is a surrogate marker for the efficacy of EGFR-TKIs but is not an indication of acquired resistance to EGFR-TKIs in NSCLC patients with EGFR mutationsm

Lignende værker

• Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance
  af: Wu, Wen-Shuo, et al.
  Udgivet: (2014)
• Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
  af: Wen, Miaomiao, et al.
  Udgivet: (2018)
• PKCδ-mediated SGLT1 upregulation confers the acquired resistance of NSCLC to EGFR TKIs
  af: Chen, Chia-Hung, et al.
  Udgivet: (2021)
• Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
  af: Wei, Zhigang, et al.
  Udgivet: (2017)
• Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients
  af: Xiong, Liwen, et al.
  Udgivet: (2017)